Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel growth. However, the implementation of this strategy has faced two major obstacles. First, the long-term shutdown of tumour blood vessels by the anti-angiogenesis agent can prevent the tumour from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the intra-tumoural accumulation of hypoxia-inducible factor-1alpha (HIF1-alpha); overexpression of HIF1-alpha is correlated with increased tumour invasiveness and resistance to chemotherapy. Here we report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to solid tumours. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumour. The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumour, then releases a chemotherapy agent. This focal release within a tumour results in improved therapeutic index with reduced toxicity. The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an 'integrative' approach in cancer therapy.
Sengupta
Shiladitya
S
Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Eavarone
David
D
Capila
Ishan
I
Zhao
Ganlin
G
Watson
Nicki
N
Kiziltepe
Tanyel
T
Sasisekharan
Ram
R
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001632:Bibenzyls / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000473:pathology; D018920:Coculture Techniques; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000473:pathology; D006801:Humans; D008546:Melanoma, Experimental / Q000098:blood supply / Q000473:pathology; D051379:Mice; D036103:Nanotechnology / Q000379:methods*; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013267:Stilbenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors; D014018:Tissue Distribution
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001632:Bibenzyls; D013267:Stilbenes; C040105:combretastatin; D004317:Doxorubicin